(Q36715742)

15 August 2017

1 reference

title

Investigational treatments for postoperative surgical site infections (English)

1 reference

15 August 2017

2

Helen Giamarellou

1 reference

15 August 2017

Garyphallia Poulakou

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

16

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

137-155

1 reference

Epidemiology of drug resistance: implications for a post-antimicrobial era

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antimicrobial resistance trends and outbreak frequency in United States hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Multi-resistant Gram-negative bacilli: from epidemics to endemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Trends in antimicrobial drug development: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

The abandonment of antibacterials: why and wherefore?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antimicrobial resistance of Acinetobacter spp. in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Clinical experience with recently approved antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Thrombocytopenia associated with linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Hematologic effects of linezolid: summary of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Linezolid-induced inhibition of mitochondrial protein synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Treatment options for vancomycin-resistant enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Quinupristin/dalfopristin: a therapeutic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Safety and tolerability of quinupristin/dalfopristin: administration guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Tigecycline: a new glycylcycline antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of tigecycline against the Bacteroides fragilis group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Tigecycline: what is it, and where should it be used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Severe myopathy and possible hepatotoxicity related to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Treatment options for multidrug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Dalbavancin: a new option for the treatment of gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Glycopeptides: Update on an old successful antibiotic class

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Effect of dalbavancin on the normal intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of faropenem against 579 strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

New advances in antibiotic development and discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Activities of doripenem (S-4661) against drug-resistant clinical pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Beta-lactams against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Emergence of fluoroquinolone resistance among Bacteroides species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activity of the new quinolone WCK 771 against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Prulifloxacin: a new antibacterial fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Oritavancin: a new avenue for resistant Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Telavancin: in vitro activity against staphylococci in a biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Oxazolidinone antibacterial agents: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Dihydrofolate reductase inhibitors as antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Therapeutic potential of peptide deformylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Triclosan inhibition of fatty acid synthesis and its effect on growth of Escherichia coli and Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

The reductase steps of the type II fatty acid synthase as antimicrobial targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Discovery of FabH/FabF inhibitors from natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Characterization and inhibitor discovery of one novel malonyl-CoA: acyl carrier protein transacylase (MCAT) from Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Anti-Clumping Factor A Immunoglobulin Reduces the Duration of Methicillin-ResistantStaphylococcus aureusBacteremia in an Experimental Model of Infective Endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Prospects for active and passive immunization against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Contributions to the management of intraabdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.2.137

Trichostatin D, a new inducer of phenotypic reversion in transformed cells.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.179

Identifiers

DOI

10.1517/13543784.16.2.137

1 reference

15 August 2017

1 reference